New drug hopes to ease sickle cell pain by boosting fetal hemoglobin

NCT ID NCT06546670

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 6 times

Summary

This study tests a new drug called ITU512 in healthy people and those with sickle cell disease. The goal is to see if it is safe and can increase fetal hemoglobin, which may reduce sickle cell symptoms. The trial is in early phases (1 and 2) and involves about 161 participants. It is not a cure, but aims to control the disease by boosting the body's own protective hemoglobin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Boston Childrens Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Childrens Hospital Of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
East Carolina University
RECRUITING

Greenville, North Carolina, 27858, United States
Lifespan
RECRUITING

Providence, Rhode Island, 02903, United States
Novartis Investigative Site
RECRUITING

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Adana, Yuregir, 01250, Turkey (Türkiye)
Quotient Sciences Sea View
COMPLETED

Miami, Florida, 33126, United States
UT Health Science Center
RECRUITING

Houston, Texas, 77030, United States
University of Alabama Birmingham
RECRUITING

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.